Real-world Patient Experiences With Inbrija®

Study acronym: INHALE-PD
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Site details revised at 2 of 2 sites
  2. Trial status changed: Recruiting → Not Yet Recruiting
    • Start date pushed from Aug 26, 2026 to Sep 2026
    • Study sites: 1 to 2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing. This study aims to explore the experiences of people with Parkinson's disease who are prescribed Inbrija® as part of their usual care. Through a mixed-methods approach, the study will examine how OFF episodes affect patients, what influences their decision to use Inbrija®, and whether patient-reported outcomes related to symptoms, daily functioning, and quality of life change during the first 3 months of treatment. The study is planned to be conducted at approximately 7 sites in Austria, Germany, and Sweden and will enroll up to 120 participants receiving Inbrija® in routine clinical practice.
Trial Details
NCT Number NCT07797790
Lead Sponsor Merz Therapeutics GmbH
Conditions
(from sponsor)		 Parkinson Disease (PD), Parkinson's Disease, Off Episodes of Parkinson Disease
Related terms Fatigue, Parkinson Disease, Social Stigma
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov